135 related articles for article (PubMed ID: 21154125)
1. Necitumumab, a fully human IgG1 mAb directed against the EGFR for the potential treatment of cancer.
Dienstmann R; Tabernero J
Curr Opin Investig Drugs; 2010 Dec; 11(12):1434-41. PubMed ID: 21154125
[TBL] [Abstract][Full Text] [Related]
2. A phase I pharmacologic study of necitumumab (IMC-11F8), a fully human IgG1 monoclonal antibody directed against EGFR in patients with advanced solid malignancies.
Kuenen B; Witteveen PO; Ruijter R; Giaccone G; Dontabhaktuni A; Fox F; Katz T; Youssoufian H; Zhu J; Rowinsky EK; Voest EE
Clin Cancer Res; 2010 Mar; 16(6):1915-23. PubMed ID: 20197484
[TBL] [Abstract][Full Text] [Related]
3. Necitumumab in the treatment of advanced non-small cell lung cancer: translation from preclinical to clinical development.
Dienstmann R; Felip E
Expert Opin Biol Ther; 2011 Sep; 11(9):1223-31. PubMed ID: 21679088
[TBL] [Abstract][Full Text] [Related]
4. A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor.
Ciardiello F; Tortora G
Clin Cancer Res; 2001 Oct; 7(10):2958-70. PubMed ID: 11595683
[TBL] [Abstract][Full Text] [Related]
5. Receptor kinase inhibitors target NSCLC: two antibodies and a small-molecule MET inhibitor.
Yee D
BioDrugs; 2011 Aug; 25(4):271-3. PubMed ID: 21815704
[TBL] [Abstract][Full Text] [Related]
6. Population Pharmacokinetics of Necitumumab in Cancer Patients.
Long A; Chigutsa E; Wallin J
Clin Pharmacokinet; 2017 May; 56(5):505-514. PubMed ID: 27696220
[TBL] [Abstract][Full Text] [Related]
7. Necitumumab for the treatment of stage IV metastatic squamous non-small-cell lung cancer.
Sacco PC; Maione P; Rossi A; Sgambato A; Casaluce F; Palazzolo G; Gridelli C
Expert Rev Respir Med; 2015 Jun; 9(3):245-54. PubMed ID: 25797462
[TBL] [Abstract][Full Text] [Related]
8. Necitumumab: a new option for first-line treatment of squamous cell lung cancer.
Jiménez Aguilar E; Zugazagoitia Fraile J; Paz-Ares Rodríguez L
Expert Opin Drug Metab Toxicol; 2018 Aug; 14(8):765-772. PubMed ID: 30025476
[TBL] [Abstract][Full Text] [Related]
9. Necitumumab for the treatment of advanced non-small-cell lung cancer.
Díaz-Serrano A; Sánchez-Torre A; Paz-Ares L
Future Oncol; 2019 Mar; 15(7):705-716. PubMed ID: 30501503
[TBL] [Abstract][Full Text] [Related]
10. Is there still room for large registrative trials in unselected cancer patients? The case of anti-epidermal growth factor receptor antibodies in advanced non-small-cell lung cancer.
Di Maio M
Expert Opin Biol Ther; 2011 Sep; 11(9):1131-3. PubMed ID: 21806477
[TBL] [Abstract][Full Text] [Related]
11. Epidermal growth factor receptor-directed monoclonal antibodies in nonsmall cell lung cancer: an update.
Pirker R
Curr Opin Oncol; 2015 Mar; 27(2):87-93. PubMed ID: 25636162
[TBL] [Abstract][Full Text] [Related]
12. Necitumumab for non-small cell lung cancer.
Greillier L; Tomasini P; Barlesi F
Expert Opin Biol Ther; 2015; 15(8):1231-9. PubMed ID: 26051700
[TBL] [Abstract][Full Text] [Related]
13. Cetuximab (Imclone/Merck/Bristol-Myers Squibb).
Kies MS; Harari PM
Curr Opin Investig Drugs; 2002 Jul; 3(7):1092-100. PubMed ID: 12186273
[TBL] [Abstract][Full Text] [Related]
14. Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer.
Wong SF
Clin Ther; 2005 Jun; 27(6):684-94. PubMed ID: 16117976
[TBL] [Abstract][Full Text] [Related]
15. Monoclonal antibodies against EGFR in non-small cell lung cancer.
Pirker R; Filipits M
Crit Rev Oncol Hematol; 2011 Oct; 80(1):1-9. PubMed ID: 21109448
[TBL] [Abstract][Full Text] [Related]
16. Phase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptor.
Vanhoefer U; Tewes M; Rojo F; Dirsch O; Schleucher N; Rosen O; Tillner J; Kovar A; Braun AH; Trarbach T; Seeber S; Harstrick A; Baselga J
J Clin Oncol; 2004 Jan; 22(1):175-84. PubMed ID: 14701780
[TBL] [Abstract][Full Text] [Related]
17. Necitumumab for the treatment of squamous cell non-small cell lung cancer.
Brinkmeyer JK; Moore DC
J Oncol Pharm Pract; 2018 Jan; 24(1):37-41. PubMed ID: 27913776
[TBL] [Abstract][Full Text] [Related]
18. The EGF receptor family as targets for cancer therapy.
Mendelsohn J; Baselga J
Oncogene; 2000 Dec; 19(56):6550-65. PubMed ID: 11426640
[TBL] [Abstract][Full Text] [Related]
19. Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225.
Ciardiello F; Bianco R; Damiano V; De Lorenzo S; Pepe S; De Placido S; Fan Z; Mendelsohn J; Bianco AR; Tortora G
Clin Cancer Res; 1999 Apr; 5(4):909-16. PubMed ID: 10213228
[TBL] [Abstract][Full Text] [Related]
20. Epidermal growth factor receptor inhibitors in cancer treatment.
Ciardiello F
Future Oncol; 2005 Apr; 1(2):221-34. PubMed ID: 16555994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]